XML 77 R67.htm IDEA: XBRL DOCUMENT
v3.23.2

Segment Reporting - Sales from Products (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022
Segment Reporting Information [Line Items] |  |  |  |
Sales | $ 15,035 | $ 14,593 | $ 29,522 | $ 30,494
Increase in hedge revenue |  |  | 128 | 277
Revenue related to the sale of the marketing rights |  |  | 54 | 146
U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 7,018 | 6,238 | 13,676 | 13,577
Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 8,018 | 8,355 | 15,846 | 16,917
Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 14,913 | 14,223 | 29,126 | 29,812
Operating Segments | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 7,045 | 6,203 | 13,644 | 13,449
Operating Segments | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 7,869 | 8,020 | 15,482 | 16,362
Corporate, Non-Segment |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 122 | 370 | 396 | 682
Corporate, Non-Segment | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | (27) | 35 | 32 | 128
Corporate, Non-Segment | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 149 | 335 | 364 | 555
Pharmaceutical | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 13,457 | 12,756 | 26,179 | 26,863
Pharmaceutical | Operating Segments | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 6,570 | 5,726 | 12,688 | 12,498
Pharmaceutical | Operating Segments | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 6,887 | 7,030 | 13,491 | 14,364
Pharmaceutical | Operating Segments | Keytruda |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 6,271 | 5,252 | 12,065 | 10,061
Pharmaceutical | Operating Segments | Keytruda | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 3,863 | 3,197 | 7,348 | 5,976
Pharmaceutical | Operating Segments | Keytruda | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 2,408 | 2,055 | 4,718 | 4,085
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 310 | 275 | 585 | 541
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 144 | 143 | 286 | 283
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 166 | 132 | 299 | 257
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 242 | 231 | 474 | 459
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 163 | 128 | 316 | 284
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 79 | 103 | 158 | 175
Pharmaceutical | Operating Segments | Welireg |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 50 | 27 | 92 | 45
Pharmaceutical | Operating Segments | Welireg | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 49 | 27 | 90 | 45
Pharmaceutical | Operating Segments | Welireg | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 2 | 0 | 3 | 0
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 47 | 33 | 90 | 86
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 36 | 28 | 66 | 55
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 11 | 5 | 24 | 30
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 2,458 | 1,674 | 4,430 | 3,133
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 464 | 428 | 880 | 846
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1,994 | 1,245 | 3,550 | 2,287
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 582 | 578 | 1,109 | 1,047
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 447 | 434 | 868 | 805
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 135 | 143 | 242 | 243
Pharmaceutical | Operating Segments | RotaTeq |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 131 | 173 | 428 | 389
Pharmaceutical | Operating Segments | RotaTeq | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 93 | 98 | 273 | 273
Pharmaceutical | Operating Segments | RotaTeq | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 37 | 75 | 155 | 116
Pharmaceutical | Operating Segments | Vaxneuvance |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 168 | 12 | 274 | 16
Pharmaceutical | Operating Segments | Vaxneuvance | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 147 | 11 | 241 | 16
Pharmaceutical | Operating Segments | Vaxneuvance | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 20 | 0 | 33 | 1
Pharmaceutical | Operating Segments | Pneumovax 23 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 92 | 153 | 188 | 325
Pharmaceutical | Operating Segments | Pneumovax 23 | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 23 | 94 | 63 | 212
Pharmaceutical | Operating Segments | Pneumovax 23 | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 69 | 59 | 125 | 114
Pharmaceutical | Operating Segments | Vaqta |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 42 | 35 | 82 | 71
Pharmaceutical | Operating Segments | Vaqta | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 29 | 16 | 59 | 45
Pharmaceutical | Operating Segments | Vaqta | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 13 | 19 | 23 | 25
Pharmaceutical | Operating Segments | Bridion |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 502 | 426 | 989 | 821
Pharmaceutical | Operating Segments | Bridion | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 299 | 237 | 576 | 432
Pharmaceutical | Operating Segments | Bridion | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 203 | 190 | 413 | 389
Pharmaceutical | Operating Segments | Prevymis |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 143 | 103 | 273 | 197
Pharmaceutical | Operating Segments | Prevymis | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 61 | 47 | 116 | 87
Pharmaceutical | Operating Segments | Prevymis | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 82 | 56 | 157 | 110
Pharmaceutical | Operating Segments | Dificid |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 76 | 66 | 141 | 119
Pharmaceutical | Operating Segments | Dificid | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 68 | 63 | 130 | 113
Pharmaceutical | Operating Segments | Dificid | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 8 | 3 | 11 | 6
Pharmaceutical | Operating Segments | Primaxin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 53 | 64 | 133 | 122
Pharmaceutical | Operating Segments | Primaxin | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | (2) | 0 | 2 | 1
Pharmaceutical | Operating Segments | Primaxin | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 56 | 64 | 132 | 122
Pharmaceutical | Operating Segments | Noxafil |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 55 | 60 | 116 | 118
Pharmaceutical | Operating Segments | Noxafil | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 11 | 16 | 25 | 25
Pharmaceutical | Operating Segments | Noxafil | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 45 | 45 | 91 | 92
Pharmaceutical | Operating Segments | Zerbaxa |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 54 | 46 | 104 | 76
Pharmaceutical | Operating Segments | Zerbaxa | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 30 | 22 | 57 | 40
Pharmaceutical | Operating Segments | Zerbaxa | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 24 | 24 | 47 | 36
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 68 | 98 | 167 | 170
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 70 | 88 | 153 | 159
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | (2) | 10 | 14 | 11
Pharmaceutical | Operating Segments | Adempas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 65 | 63 | 125 | 124
Pharmaceutical | Operating Segments | Adempas | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Pharmaceutical | Operating Segments | Adempas | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 65 | 63 | 125 | 124
Pharmaceutical | Operating Segments | Lagevrio |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 203 | 1,177 | 595 | 4,424
Pharmaceutical | Operating Segments | Lagevrio | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 2 | 0 | 0 | 1,523
Pharmaceutical | Operating Segments | Lagevrio | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 201 | 1,177 | 595 | 2,901
Pharmaceutical | Operating Segments | Isentress/Isentress HD |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 136 | 147 | 259 | 305
Pharmaceutical | Operating Segments | Isentress/Isentress HD | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 56 | 67 | 108 | 128
Pharmaceutical | Operating Segments | Isentress/Isentress HD | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 80 | 80 | 151 | 177
Pharmaceutical | Operating Segments | Belsomra |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 63 | 69 | 119 | 137
Pharmaceutical | Operating Segments | Belsomra | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 21 | 19 | 37 | 39
Pharmaceutical | Operating Segments | Belsomra | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 42 | 50 | 82 | 98
Pharmaceutical | Operating Segments | Simponi |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 180 | 181 | 359 | 366
Pharmaceutical | Operating Segments | Simponi | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Pharmaceutical | Operating Segments | Simponi | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 180 | 181 | 359 | 366
Pharmaceutical | Operating Segments | Remicade |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 48 | 53 | 99 | 114
Pharmaceutical | Operating Segments | Remicade | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Pharmaceutical | Operating Segments | Remicade | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 48 | 53 | 99 | 114
Pharmaceutical | Operating Segments | Januvia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 511 | 756 | 1,062 | 1,535
Pharmaceutical | Operating Segments | Januvia | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 243 | 301 | 514 | 626
Pharmaceutical | Operating Segments | Januvia | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 267 | 455 | 548 | 909
Pharmaceutical | Operating Segments | Janumet |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 354 | 476 | 683 | 931
Pharmaceutical | Operating Segments | Janumet | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 82 | 105 | 138 | 168
Pharmaceutical | Operating Segments | Janumet | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 272 | 371 | 544 | 762
Pharmaceutical | Operating Segments | Other pharmaceutical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 553 | 528 | 1,138 | 1,131
Pharmaceutical | Operating Segments | Other pharmaceutical | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 171 | 157 | 342 | 317
Pharmaceutical | Operating Segments | Other pharmaceutical | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 382 | 372 | 793 | 814
Animal Health | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1,456 | 1,467 | 2,947 | 2,949
Animal Health | Operating Segments | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 475 | 477 | 956 | 951
Animal Health | Operating Segments | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 982 | 990 | 1,991 | 1,998
Animal Health | Operating Segments | Livestock |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 807 | 826 | 1,656 | 1,658
Animal Health | Operating Segments | Livestock | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 165 | 164 | 338 | 335
Animal Health | Operating Segments | Livestock | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 643 | 662 | 1,318 | 1,322
Animal Health | Operating Segments | Companion Animal |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 649 | 641 | 1,291 | 1,291
Animal Health | Operating Segments | Companion Animal | U.S. |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 310 | 313 | 618 | 616
Animal Health | Operating Segments | Companion Animal | Int’l |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | $ 339 | $ 328 | $ 673 | $ 676

X
- Definition Increase (Decrease) In Hedge Revenue + References No definition available. + Details
Name: | mrk_IncreaseDecreaseInHedgeRevenue
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12 + Details
Name: | us-gaap_ProceedsFromSaleOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=mrk_InternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_KeytrudaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LenvimaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_WeliregMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AllianceRevenueReblozylMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RotateqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_VaxneuvanceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_Pneumovax23Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_VaqtaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BridionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_PrevymisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_DificidMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_PrimaxinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_NoxafilMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ZerbaxaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AllianceRevenueAdempasVerquvoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AdempasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LagevrioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_IsentressIsentressHDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BelsomraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_SimponiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanuviaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanumetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LivestockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CompanionAnimalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |